PsA RZB KEEPsAKE | Nov

US Medical Affairs Rheumatology logo

Experts Discuss:
Psoriasis for Rheumatologists

Video

Dr. Saakshi Khattri and Dr. Shikha Singla discuss IMMpulse, a head-to-head trial of risankizumab and apremilast in moderate PsO, and what rheumatologists could apply from PsO studies when making clinical decisions for their patients with PsA.1

  •  10-minute watch

The experts

Saakshi Khattri, MD, Profile image

Saakshi Khattri, MD

Rheumatologist and Dermatologist, Icahn School of Medicine at Mount Sinai, New York, New York

Shikha Singla, MD, Profile image

Shikha Singla, MD

Rheumatologist at Froedtert & Medical College of Wisconsin in Milwaukee, Wisconsin

Key information

Some patients with PsO are at risk for developing PsA:
decorative

1 in 4

patients with PsO develop PsA2

The treatment landscape for PsO and PsA is evolving:

decorative

Many therapies for PsO are also effective in treating PsA3,4

PASI 75

Historically, PASI 75 has been the most commonly reported primary endpoint in PsO trials5
decorative
decorative

PASI 90

In recent years, PsO trials are using the more stringent primary endpoint of PASI 906
decorative
Data from head-to-head PsO trials can be important for rheumatologists to consider when making clinical decisions for patients with PsA

Abbreviations: PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis.

decorative

How often do you review clinical studies in PsO?

Not often Very often

decorative

How often do you manage PsO or skin symptoms in your patients with PsA?

Not often Very often

decorative

How likely are you to consult with a dermatologist when managing a patient 
with PsA?

Very unlikely Very likely

Resource

PDF icon

Find out more about the IMMpulse trial

Download infographic

Indications

Risankizumab-rzaa, a humanized monoclonal antibody to IL-23, is indicated for the treatment of active psoriatic arthritis in adults and for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important safety considerations

Risankizumab is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, may occur. If a serious hypersensitivity reaction occurs, discontinue risankizumab and initiate appropriate therapy immediately. Risankizumab may increase the risk of infections. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, discontinue risankizumab until the infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with risankizumab. Avoid use of live vaccines in patients treated with risankizumab. The most common adverse reactions (≥1%) are upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Please review risankizumab-rzaa full Prescribing Information for additional information by visiting www.rxabbvie.com or contact AbbVie Medical Information at 1-800-633-9110.

Explore more posts about risankizumab in PsA

Image of a Selective IL-23 p19 inhibitor
The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis
 10 minute read
Profile image of Philip Mease, MD and Saakshi Khattri, MD
Composite Measures to Inform Management of Bio-naïve Patients with Psoriatic Arthritis
 5 minute read/20 minute listen

References:
1. Stein Gold LF et al. Br J Dermatol. 2023. doi: 10.1093/bjd/ljad252. Online ahead of print.
2. Alinaghi F et al. J Am Acad Dermatol. 2019; 80: 251–65.
3. ten Bergen LL, et al. Scand J Immunol. 2020;92(4):e12946.
4. Duffin KC, et al. J Rheumatol. 2023;50:131–143.
5. Ogdie A, et al. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):81–109.
6. Kirsten N et al. Life (Basel). 2021;11(11):1151.

We value your feedback

The US Medical Affairs department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.
© 2023 AbbVie Inc. All rights reserved. RISN-US-00022-MC v1.0 Approved October 2023